Open AccessReal-world insight on apremilast therapy in patients with plaque psoriasis: Indian experience
Author(s) -
Abhishek De,
Sudip Das,
Dhiraj Dhoot,
Aarti Sarda
Publication year - 2020
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_194_19
Subject(s) - apremilast , medicine , psoriasis , adverse effect , psoriatic arthritis , dermatology , diarrhea , clinical trial , plaque psoriasis
Psoriasis is an immune-mediated inflammatory skin disorder, which follows a chronic course. Apremilast is a novel phosphodiesterase 4 (PDE4) inhibitor, approved by US-FDA for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. A majority of the data related to the effectivity and safety of apremilast use in psoriasis is extracted from clinical trials. The present study was planned to get an insight into real-world experience with the use of apremilast in patients with moderate-to-severe plaque psoriasis related to its effectiveness and safety in India.